Detection of HER2 expression using ^99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial.

"Declarations Ethics approval and consent to participateThis study was approved by the Ethics Committee of Shanghai General Hospital (2020[84]), and all participants signed an informed consent form. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This research was supported by the Clinical Research Plan of the SHDC (SHDC2020CR2057B) and the National Natural Science Foundation of China (81971647, 82171978, and U2267221)."

"Trial registration NCT04674722, Date of registration: December 19, 2020."